Making genuine progress against metastatic breast cancer

Journal of Clinical Oncology

Volumn 30, Issue 28, 2012, Pages 3448-3451

  Lyman, Gary H ^a   Burstein, Harold J ^b   Buzdar, Aman U ^c   D'Agostino, Ralph ^d   Ellis, Paul A ^e  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d BOSTON UNIVERSITY   (United States)

^e GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; DOCETAXEL; PACLITAXEL;

ADVANCED CANCER; BREAST CANCER; CANCER MORTALITY; DRUG APPROVAL; DRUG INDICATION; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; METASTASIS; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNITED STATES;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG APPROVAL; ENDPOINT DETERMINATION; FEMALE; HUMANS; NEOPLASM METASTASIS; SURVIVAL RATE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84867084209     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.6931     Document Type: Note

References (31)

1. Burstein HJ: Avastin for breast cancer, 2005-2011: Requiescat in pacem? J Natl Compr Canc Netw 9:1321-1323, 2011
2. Cortés J, Calvo E, González-Martín A, et al: Progress against solid tumors in danger: The metastatic breast cancer example. J Clin Oncol 30:3444-3447, 2012
3. US Department of Health and Human Services, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research: Guidance for industry. Clinical trial endpoints for the approval of cancer drugs and biologics. http://www.fda.gov/downloads/Drug/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf
4. Cortazar P, Justice R, Johnson J, et al: US Food and Drug Administration approval overview in metastatic breast cancer. J Clin Oncol 30:1705-1711, 2012
5. US Food and Drug Administration: Guidance for industry: Applications covered by section 505(b)(2). http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm079345.pdf
6. Johnson JR, Ning YM, Farrell A, et al: Accelerated approval of oncology products: The Food and Drug Administration experience. J Natl Cancer Inst 103:636-644, 2011
7. D'Agostino RB Sr: Changing end points in breast-cancer drug approval: The Avastin story. N Engl J Med 365:e2, 2011
8. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005 (Pubitemid 46224178)
9. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
10. Cella D, Wang M, Wagner L, et al: Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: Results from Eastern Cooperative Oncology Group Study 2100 (E2100). Breast Cancer Res Treat 130:855-861, 2011
11. Miles DW, Chan A, Dirix LY, et al: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239-3247, 2010
12. Robert NJ, Diéras V, Glaspy J, et al: RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252-1260, 2011
13. US Food and Drug Administration: Commissioner statement: FDA commissioner removes breast cancer indication from Avastin label. http://www.fda.gov/ NewsEvents/Newsroom/UCM279485
14. US Food and Drug Administration: 2010 meeting materials, Oncologic Drugs Advisory Committee. http://www.fda.gov/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ucm195226.htm
15. Booth CM, Eisenhauer EA: Progression-free survival: Meaningful or simply measurable? J Clin Oncol 30:1030-1033, 2012
16. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al: Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 26:1987-1992, 2008
17. Hackshaw A, Knight A, Barrett-Lee P, et al: Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer. Br J Cancer 93:1215-1221, 2005 (Pubitemid 41679406)
18. Miksad RA, Zietemann V, Gothe R, et al: Progression-free survival as a surrogate endpoint in advanced breast cancer. Int J Technol Assess Health Care 24:371-383, 2008
19. Sherrill B, Amonkar M, Wu Y, et al: Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. Br J Cancer 99:1572-1578, 2008
20. Broglio KR, Berry DA: Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101:1642-1649, 2009
21. Korn EL, Freidlin B, Abrams JS: Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol 29:2439-2442, 2011
22. Verma S, McLeod D, Batist G, et al: In the end what matters most? A review of clinical endpoints in advanced breast cancer. Oncologist 16:25-35, 2011
23. Cardoso F, Costa A, Norton L, et al: 1st international consensus guidelines for advanced breast cancer (ABC 1). Breast 21:242-252, 2012
24. Gianni L, Romieu G, Lichinstser M, et al: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab in combination with trastuzumab + docetaxel as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. Cancer Res 71:S4-S8, 2011. http://www.abstracts2view.com/sabcs11/view.php?nu=SABCS11L-3034
25. Montero AJ, Vogel C: Fighting fire with fire: Rekindling the bevacizumab debate. N Engl J Med 366:374-375, 2012
26. Burstein HJ: Bevacizumab for advanced breast cancer: All tied up with a RIBBON? J Clin Oncol 29:1232-1235, 2011
27. Burstein HJ: Avastin, ODAC, and the FDA: Are we drafting the right players? J Natl Compr Canc Netw 8:833-834, 2010
28. Panageas KS, Ben-Porat L, Dickler MN, et al: When you look matters: The effect of assessment schedule on progression-free survival. J Natl Cancer Inst 99:428-432, 2007 (Pubitemid 47073565)
29. Fleming TR, Rothmann MD, Lu HL: Issues in using progression-free survival when evaluating oncology products. J Clin Oncol 27:2874-2880, 2009
30. Dedes KJ, Matter-Walstra K, Schwenkglenks M, et al: Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation. Eur J Cancer 45:1397-1406, 2009
31. Baselga J, Cortes J, Kim S, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012